Answer
In Madopar, benserazide inhibits peripheral decarboxylase, blocking levodopa conversion to dopamine outside the brain, thereby reducing gastrointestinal side effects and enabling a more rapid initial response and simpler dosage regimen.
Sources for this answer
- Madopar CR 100 mg/25 mg Prolonged Release Hard CapsulesRoche Products Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 18Document updated
Sources checked